Cancer Biomarker Market: By Biomarker Type (Protein Biomarker, Genetic Biomarker, Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Non-Hodgkin's Lymphoma, Bladder Cancer, Kidney Cancer, Liver Cancer, Others), By Profiling Technology (OMICS Technology, Imaging Technology, Immunoassays, Cytogenetics, Bioinformatics, Others), By Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Others), and Geography  

Cancer Biomarker Market size was valued at USD 15.06 billion in 2022 and expected to reach USD 31.53 billion by 2029 witnessing a CAGR rate of 11.5% from 2023-2029. For instance, according to WHO 2018 data, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, a rise in R&D for the development of newer biomarkers, rise in funding from public and private sectors, an increase in the adoption of cancer biomarkers for drug discovery and development, and a surge in demand for early-stage disease diagnosis are expected to propel the market over the forecast years. However, stringent regulations for product approval, high costs for the R&D, and lack of favorable reimbursement guidelines are hampering the growth of the market over the forecast years. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.